Abbott Zemplar For Hyperparathyroidism Will Be Available By End Of May
Executive Summary
Abbott will launch Zemplar, its second injectable synthetic vitamin D analogue for use in chronic renal failure patients, by the end of May.
You may also be interested in...
Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target
Amgen's chronic kidney disease therapy Sensipar will be available within the next few weeks following FDA's March 8 approval, the company said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011